ADAPTOGENICS HEALT
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 709
- Market Cap
- $684.2M
- Introduction
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA.
ImmuneSenseâ„¢ IBD Study
- Conditions
- Inflammatory Bowel Diseases
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 484
- Registration Number
- NCT05769829
- Locations
- 🇺🇸
University Gastroenterology, Providence, Rhode Island, United States
🇺🇸Frontier Clinical Research, LLC, Uniontown, Pennsylvania, United States
🇺🇸Gastroenterology Consultants of South Texas, PA, Brownsville, Texas, United States
Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy
- Conditions
- Follicular LymphomaDiffuse Large B Cell LymphomaMantle Cell Lymphoma
- Interventions
- Device: ClonoSEQ
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 300
- Registration Number
- NCT05255354
- Locations
- 🇺🇸
Stanford Cancer Center, Palo Alto, California, United States
ImmuneSenseâ„¢ COVID-19 Cross-Reactivity Study
- Conditions
- SARS-CoV-2 InfectionCoronavirus Disease
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Adaptive Biotechnologies
- Registration Number
- NCT05112874
- Locations
- 🇺🇸
Adaptive Biotechnologies, Seattle, Washington, United States
ImmuneSense COVID-19 Variant Study
- Conditions
- Covid19
- Interventions
- Device: T-Detect COVID test
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2022-12-07
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 203
- Registration Number
- NCT05054088
- Locations
- 🇺🇸
Decentralized Trial Model- Modesto, Modesto, California, United States
🇺🇸Decentralized Trial Model- Sacramento, Sacramento, California, United States
🇺🇸Decentralized Trial Model - Washington D.C., Washington, District of Columbia, United States
ImmuneSenseâ„¢ COVID-19 Study
- Conditions
- Coronavirus Disease (COVID-19)SARS-CoV-2 Infection
- Interventions
- Other: T-Detectâ„¢ SARS-CoV-2 Assay
- First Posted Date
- 2020-10-12
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 180
- Registration Number
- NCT04583982
- Locations
- 🇺🇸
Adaptive Biotechnologies Clinical Investigational Site, Secaucus, New Jersey, United States
The clonoSEQ® Watch Registry
- Conditions
- Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia, Adult B-CellMultiple Myeloma
- Interventions
- Diagnostic Test: clonoSEQ Assay
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 465
- Registration Number
- NCT04545333
- Locations
- 🇺🇸
University of Washington, Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Oregon Health & Science University, Knight Cancer Institute, Portland, Oregon, United States
ImmuneRACE - Immune Response Action to COVID-19 Events
- Conditions
- Covid19
- First Posted Date
- 2020-07-31
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 808
- Registration Number
- NCT04494893
- Locations
- 🇺🇸
Adaptive Biotechnologies, Seattle, Washington, United States
ImmuneSense Lyme Study
- Conditions
- Lyme Disease
- Interventions
- Diagnostic Test: T-Detect Lyme
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- Adaptive Biotechnologies
- Target Recruit Count
- 893
- Registration Number
- NCT04422314
- Locations
- 🇺🇸
Adaptive Biotechnologies Investigational Site, Wauwatosa, Wisconsin, United States